Department of Biology, Centre for Blood Research, York Biomedical Research Institute, University of York, York, United Kingdom.
Cambridge Institute for Medical Research, Cambridge Biomedical Campus, University of Cambridge, Cambridge, United Kingdom.
Blood. 2024 Aug 29;144(9):931-939. doi: 10.1182/blood.2023019986.
Ribosomopathy Shwachman-Diamond syndrome (SDS) is a rare autosomal recessive inherited bone marrow failure syndrome (IBMFS) caused by mutations in the Shwachman-Bodian-Diamond syndrome gene, which is associated with an increased risk of myeloid malignancy. Tracking how hematopoietic stem cell (HSC) clonal dynamics change over time, assessing whether somatic genetic rescue mechanisms affect these dynamics, and mapping out when leukemic driver mutations are acquired is important to understand which individuals with SDS may go on to develop leukemia. In this review, we discuss how new technologies that allow researchers to map mutations at the level of single HSC clones are generating important insights into genetic rescue mechanisms and their relative risk for driving evolution to leukemia, and how these data can inform the future development of personalized medicine approaches in SDS and other IBMFSs.
核糖体病 Shwachman-Diamond 综合征(SDS)是一种罕见的常染色体隐性遗传骨髓衰竭综合征(IBMFS),由 Shwachman-Bodian-Diamond 综合征基因的突变引起,与髓系恶性肿瘤的风险增加有关。跟踪造血干细胞(HSC)克隆动力学随时间的变化,评估体细胞遗传拯救机制是否影响这些动力学,以及阐明何时获得白血病驱动突变,对于了解哪些 SDS 患者可能会发展为白血病非常重要。在这篇综述中,我们讨论了允许研究人员在单个 HSC 克隆水平上绘制突变的新技术如何为遗传拯救机制及其向白血病进化的相对风险提供重要的见解,以及这些数据如何为 SDS 和其他 IBMFS 中的个性化医学方法的未来发展提供信息。